Urinary Metal Levels Tied to Increased Risk for Later Heart Failure
By Lori Solomon HealthDay Reporter
THURSDAY, July 3, 2025 -- There are consistent associations between elevated urinary metal levels and increased heart failure risk over time across geographically diverse cohorts of adults, according to a study published online June 17 in JACC: Heart Failure.
Irene Martinez-Morata, M.D., Ph.D., from the Columbia University Mailman School of Public Health in New York City, and colleagues evaluated the prospective association of urinary metals with incident heart failure. The analysis included participants (aged 18 to 85 years) across three geographically and ethnically and racially diverse cohorts: the Multi-Ethnic Study of Atherosclerosis (6,601 individuals) and Strong Heart Study (2,917 individuals) in the United States and the Hortega Study (1,300 individuals) in Spain.
The researchers found that during 20 years of follow-up, there were significant associations per doubling of urinary metal for cadmium (pooled hazard ratio [HR], 1.15), molybdenum (HR, 1.13), and zinc (HR, 1.22). The association of one interquartile range increase in the multimetal mixture (arsenic, cadmium, molybdenum, selenium, and zinc) levels trended to increased incident heart failure across each cohort in fully adjusted models. Results for stratified models by left ventricular ejection fraction were similar to the pooled results.
"Most previous studies have assessed individual metals in isolation," said Martinez-Morata in a statement. "By examining metals as a mixture, our analysis more closely reflects real-world exposure patterns."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Study Compares Benefits, Harms of Treatments for Chronic Hives
WEDNESDAY, July 23, 2025 -- Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study...
USPSTF Guidelines of Little Value for Estimating Preeclampsia Risk in Those at Moderate Risk
WEDNESDAY, July 23, 2025 -- Moderate U.S. Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.